Tables
- Table 1. Drugs in clinical development
Class of drug Name of compound Stage of development Fluoroquinolones Moxifloxacin Phase III Diarylquinolones TMC-207 Phase II Nitroimidazoles PA-824 Phase II OPC-67683 Phase II Oxazolidinones Linezolid Phase II PNU-100480 Phase I Rifamycins Rifapentine Phase I–II Ethylenediamines SQ-109 Phase I Carbapenems Imipenem Phase I - Table 2. Pharmacological management of multi-drug resistant (MDR) tuberculosis (TB)
First-line oral drugs Injectable bactericidal drugs# Fluoroquinolones# Second-line bacteriostatic drugs Other drugs with unclear or unproven efficacy Rifampicin¶ Streptomycin Moxifloxacin Cycloserine Clofazimine Isoniazid¶ Amikacin Gatifloxacin p-aminosalicyclic acid Clarithromycin Rifabutin Kanamycin Ofloxacin Prothionamide Amoxicillin/clavulanate Ethanmbutol Capreomycin Levofloxacin Ethionamide Linezolid Pyrizinamide Terizidone Imipenem/cilastatin Thioacetazone High-dose isoniazid Order in which drugs are added to MDR-TB regimen → #: all MDR-TB regimens should include one injectable and one fluoroquinolone where possible; ¶: by definition, isolates classed as MDR will be resistant to these drugs.
Vol 20 Issue 120
Table of Contents
Update on tuberculosis: TB in the early 21st century
